Cannakeys

Unlocking the Science of Cannabis

CK Home / Cannabigerol (CBG) Cannabinoid Research

Cannabigerol (CBG) Cannabinoid Research

Cannabigerol (CBG) Research Dashboard

75

Primary Studies

66

Related Studies

141

Total Studies

Clinical Studies

0

Clinical Meta-analyses

0

Double-blind human trials

1

Clinical human trials

Pre-Clinical Studies

14

Meta-analyses/Reviews

21

Animal studies

39

Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 141 studies associated with Cannabigerol (CBG).

Here is a small sampling of Cannabigerol (CBG) studies by title:

  • In Vitro and Clinical Evaluation of Cannabigerol (CBG) Produced via Yeast Biosynthesis: A Cannabinoid with a Broad Range of Anti-Inflammatory and Skin Health-Boosting Properties
  • Will Cannabigerol Trigger Neuroregeneration after a Spinal Cord Injury? An In Vitro Answer from NSC-34 Scratch-Injured Cells Transcriptome
  • Geospatiotemporal and causal inference study of cannabis and other drugs as risk factors for female breast cancer USA 2003–2017
  • Medical Cannabis Activity Against Inflammation: Active Compounds and Modes of Action
  • Single dose and chronic oral administration of cannabigerol and cannabigerolic acid-rich hemp extract in fed and fasted dogs: Physiological effect and pharmacokinetic evaluation

Components of the Cannabigerol (CBG) Research Dashboard

  • Top medical conditions associated with Cannabigerol (CBG)
  • Proven effects in clinical trials for Cannabigerol (CBG)
  • Receptors associated with Cannabigerol (CBG)
  • Individual study details for Cannabigerol (CBG)

Ready to become a subscriber? Go to our PRICING page.

Select New Cannabinoid

Filter Cannabinoid

Members can filter by the following criteria:

  • Study Type
  • Organ Systems
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - Cannabigerol (CBG)

Description of Cannabigerol (CBG)

Cannabigerol was isolated, characterized, and synthetized by R. Mechoulan and Y. Gaoni in 1964. CBG is non-psychoactive. It is the central biosynthetic precursor to many cannabinoids. For that reason CBG is often referenced as "mother of all cannabinoids."

Other Names:

Cannabigerol

Geranylolivetol plus numerous other supplier-based synonyms.


IUPAC Name: 2-[(2E)-3,7-dimethylocta-2,6-dienyl]-5-pentylbenzene-1,3-diol


Molecular Formula: C21H32O2


Source–PubChem

Cannabigerol (CBG) Properties and Effects

CBG is:


  • An inhibitor of voltage-gated sodium (Nav) channels (M. Ghovanloo et al., 2022) 

  • Non-pychoactive (R. Mechoulam et al., 1970)

  • Muscle relaxant

  • Analgesia

  • Sedative

  • May be anti-proliferative in cases of prostate and colorectal cancer

  • Antibacterial (MRSA)

  • Appetite stimulant (in cases of anorexia, cachexia)

  • Anti-parasitical (leishmania)

  • Pre-clinical trials suggest potential benefits in treating neurological disorders such as Huntington's Disease.

Cannabigerol (CBG) Receptor Binding

Endocannabinoid system (ECS) and CBG:


Endocannabinoidome (eCBome) and CBG:


  • TRPV1 (significant agonist)

  • TRPA1 (significant agonist)

  • TRPM8 [inhibitor (antagonist)]

  • 5HT1A serotonin receptors (moderate inhibitor)

  • Alpha-2-andrenergic-receptor sites (agonist)



Ki legend:



  • Full/strong agonist Ki ~1-9nM

  • Moderate agonist Ki ~10-99nM

  • Weak agonist Ki ~100-999nM

  • Very weak agonist Ki ~1,000-up nM


(The reader is reminded that a smaller Ki is associated with the strongest effects.)

Top  

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.